Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oxurion NV's Free Cash Flow for the
six
months ended in Dec. 2025 was €-0.58 Mil. Oxurion NV's Revenue for the
six
months ended in Dec. 2025 was €0.56 Mil. Therefore, Oxurion NV's FCF Margin % for the quarter that ended in Dec. 2025 was -103.96%.
The historical rank and industry rank for Oxurion NV's FCF Margin % or its related term are showing as below:
LTS:0G99'
s FCF Margin % Range Over the Past 10 Years
Min: -68933.33 Med: -1054.48 Max: 287.68
Current: -307.21
During the past 13 years, the highest FCF Margin % of Oxurion NV was 287.68%. The lowest was -68933.33%. And the median was -1054.48%.
LTS:0G99's FCF Margin % is ranked worse than 65.05% of 950
companies
in the Biotechnology industry
Industry Median: -84.535
vs LTS:0G99: -307.21
Oxurion NV FCF Margin % Related Terms
Oxurion NV FCF Margin % Historical Data
* Premium members only.
The historical data trend for Oxurion NV's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0G99 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Oxurion NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxurion NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Oxurion NV's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxurion NV (LTS:0G99) has a FCF Margin % of -103.96% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxurion NV and its competitors. According to the industry distribution chart, Oxurion NV ranks #618 out of 950 companies in the Biotechnology industry, placing it in the top 65.1%.
Is Oxurion NV's FCF Margin % too high?
Oxurion NV's current FCF Margin % is -103.96%. Based on the distribution chart, Oxurion NV ranks #618 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oxurion NV has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Oxurion NV's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxurion NV ranks #618 out of 950 companies for FCF Margin %. This places Oxurion NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxurion NV and its competitors. Oxurion NV's current FCF Margin % is -103.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (LTS:0G99) has a current FCF Margin % of -103.96%. The stock's GF Value™ is €0.91, compared to a current price of €0.27 — trading 70% below its estimated fair value. The current FCF Margin % is -103.96%. Oxurion NV's overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Oxurion NV (LTS:0G99), the current FCF Margin % is -103.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxurion NV (LTS:0G99) Overvalued in 2026?
Based on GuruFocus' analysis, Oxurion NV stock appears to be undervalued.
The current stock price of €0.27 is trading 70% below its estimated GF Value™ of €0.91.
Key valuation signals for LTS:0G99:
FCF Margin %: -103.96%
GF Value™: €0.91 vs. price of €0.27 (70% below fair value)
No single metric tells the full story. See the LTS:0G99 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
9GF Score
Get the complete analysis for LTS:0G99
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G99 has been successfully added to your 
